GlobeNewswire·May 26, 2026, 7:00 PM ET

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova, Inc. completed the last patient last visit (LPLV) in its Phase 2 trial MN-001-NATG-202 evaluating MN-001 (tipelukast) for hypertriglyceridemia and NAFLD in patients with type 2 diabetes mellitus.
The multicenter, randomized, double-blind, placebo-controlled trial randomized patients 1:1 to receive 500 mg/day of MN-001 or placebo for 24 weeks.
Co-primary endpoints include the change from baseline in liver fat content (CAP score) and fasting serum triglycerides at Week 24, with secondary endpoints covering safety, tolerability, and lipid profile changes.
Top-line data for the study are expected in the third quarter of 2026.
MN-001 is a novel small-molecule compound with multiple mechanisms, including leukotriene receptor antagonism, phosphodiesterase inhibition, and 5-lipoxygenase inhibition to reduce inflammation \& fibrosis.
MN-001 down-regulates genes promoting fibrosis (LOXL2, Collagen Type 1, TIMP-1) \& inflammation (CCR2, MCP-1) while inhibiting triglyceride synthesis in hepatocytes.
The major metabolite MN-002 enhances cholesterol efflux in macrophages by upregulating ABCA1 \& ABCG1 transport proteins.
MediciNova has 11 clinical programs, including lead asset MN-166 (ibudilast) in Phase 3 for ALS \& DCM, with MN-001 also undergoing evaluation in a Phase 2 trial for idiopathic pulmonary fibrosis.